JPH0565233A - モノクローナル抗体含有凍結乾燥製剤 - Google Patents

モノクローナル抗体含有凍結乾燥製剤

Info

Publication number
JPH0565233A
JPH0565233A JP4041015A JP4101592A JPH0565233A JP H0565233 A JPH0565233 A JP H0565233A JP 4041015 A JP4041015 A JP 4041015A JP 4101592 A JP4101592 A JP 4101592A JP H0565233 A JPH0565233 A JP H0565233A
Authority
JP
Japan
Prior art keywords
monoclonal antibody
freeze
antigen
gelatin
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4041015A
Other languages
English (en)
Japanese (ja)
Inventor
Tamotsu Fukuda
田 保 福
Yukio Shimazaki
崎 幸 雄 島
Yasuyuki Kuroiwa
岩 保 幸 黒
Shiro Takagi
木 司 郎 高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsui Toatsu Chemicals Inc
Original Assignee
Mitsui Toatsu Chemicals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12663510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH0565233(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsui Toatsu Chemicals Inc filed Critical Mitsui Toatsu Chemicals Inc
Publication of JPH0565233A publication Critical patent/JPH0565233A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP4041015A 1991-03-08 1992-02-27 モノクローナル抗体含有凍結乾燥製剤 Pending JPH0565233A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4343191 1991-03-08
JP3-43431 1991-03-08

Publications (1)

Publication Number Publication Date
JPH0565233A true JPH0565233A (ja) 1993-03-19

Family

ID=12663510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4041015A Pending JPH0565233A (ja) 1991-03-08 1992-02-27 モノクローナル抗体含有凍結乾燥製剤

Country Status (10)

Country Link
US (1) US5908826A (OSRAM)
EP (2) EP0531539B1 (OSRAM)
JP (1) JPH0565233A (OSRAM)
AU (1) AU645187B2 (OSRAM)
CA (1) CA2082169A1 (OSRAM)
DE (2) DE69225757T2 (OSRAM)
DK (2) DK0841067T3 (OSRAM)
FI (1) FI924982L (OSRAM)
NO (1) NO924279D0 (OSRAM)
WO (1) WO1992015331A1 (OSRAM)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0805353A3 (en) * 1996-05-02 1997-11-26 Tosoh Corporation Immunoreaction agent and process for production thereof
JP2004538287A (ja) * 2001-07-25 2004-12-24 プロテイン デザイン ラブス インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JP2007217430A (ja) * 1995-07-27 2007-08-30 Genentech Inc タンパク質の処方
JPWO2005035573A1 (ja) * 2003-10-09 2008-01-17 中外製薬株式会社 タンパク質溶液の安定化方法
JPWO2005035574A1 (ja) * 2003-10-09 2008-02-14 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
JP2008303176A (ja) * 2007-06-07 2008-12-18 Kobayashi Pharmaceut Co Ltd タンパク質含有組成物
JP2010522208A (ja) * 2007-03-22 2010-07-01 イムクローン・リミテッド・ライアビリティ・カンパニー 安定な抗体処方物
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法
US8257703B2 (en) 2003-07-15 2012-09-04 Chugai Seiyaku Kabushiki Kaisha Anti-ganglioside antibodies and compositions
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6750330B1 (en) * 1998-05-14 2004-06-15 Ashley Davis Lyophilized tubulins
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
EP1698640B2 (en) * 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
WO2008051363A2 (en) * 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EA201892184A1 (ru) 2010-03-01 2019-03-29 БАЙЕР ХЕЛЬСКЕР ЛЛСи Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
HUE044038T2 (hu) 2010-11-05 2019-09-30 Novartis Ag Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
US8821865B2 (en) 2010-11-11 2014-09-02 Abbvie Biotechnology Ltd. High concentration anti-TNFα antibody liquid formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015181633A2 (en) 2014-04-11 2015-12-03 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
US10736893B2 (en) 2015-11-06 2020-08-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US20240417445A1 (en) * 2023-06-13 2024-12-19 Grifols Worldwide Operations Limited Method for producing a lyophilized composition comprising polyclonal igm and composition obtained

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2149304A (en) * 1936-04-20 1939-03-07 Sharp & Dohme Inc Lyophilic biologically active substances
SU700132A1 (ru) * 1978-06-30 1979-11-30 Томский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Вакцин И Сывороток Способ получени сухого препарата иммуноглобулина
JPS57140724A (en) * 1981-02-25 1982-08-31 Green Cross Corp:The Heat-treatment of aqueous solution containing cold insoluble globulin
JPS6035263A (ja) * 1983-08-05 1985-02-23 Wako Pure Chem Ind Ltd 不溶性担体に固定化された免疫活性物質の安定化法及び該物質を構成単位として含む生理活性物質測定用試薬
JP2565303B2 (ja) * 1984-05-25 1996-12-18 三井東圧化学株式会社 緑膿菌感染症の予防治療剤
US4650772A (en) * 1984-08-09 1987-03-17 Abbott Laboratories Monoclonal antibody stabilization
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPS6178731A (ja) * 1985-05-20 1986-04-22 Green Cross Corp:The 加熱処理免疫グロブリン製剤
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
FI883723L (fi) * 1986-12-15 1988-08-10 Mitsui Toatsu Chemicals Monoklonala maenniskoantikroppar och dessa innehaollande terapeutiska kompositioner mot infektionssjukdomar.
ES2045027T3 (es) * 1987-08-10 1994-01-16 Miles Inc Igm purificadas.
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
JPH04504253A (ja) * 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
JPH0384461A (ja) * 1989-08-28 1991-04-10 Green Cross Corp:The 免疫学的凝集反応試薬及びその製法
JPH0911350A (ja) * 1995-06-30 1997-01-14 Olympus Optical Co Ltd エネルギー硬化型樹脂を用いた光学素子の製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58167518A (ja) * 1982-03-29 1983-10-03 Nippon Sekijiyuujishiya ゼラチン誘導体添加静注用人免疫グロブリンの製造法
JPS60146833A (ja) * 1984-01-10 1985-08-02 Green Cross Corp:The モノクロ−ナル抗体製剤

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011256205A (ja) * 1995-07-27 2011-12-22 Genentech Inc タンパク質の処方
JP2017039778A (ja) * 1995-07-27 2017-02-23 ジェネンテック， インコーポレイテッド タンパク質の処方
JP2016033156A (ja) * 1995-07-27 2016-03-10 ジェネンテック， インコーポレイテッド タンパク質の処方
JP2014148555A (ja) * 1995-07-27 2014-08-21 Genentech Inc タンパク質の処方
JP2007217430A (ja) * 1995-07-27 2007-08-30 Genentech Inc タンパク質の処方
JP2007238628A (ja) * 1995-07-27 2007-09-20 Genentech Inc タンパク質の処方
EP0805353A3 (en) * 1996-05-02 1997-11-26 Tosoh Corporation Immunoreaction agent and process for production thereof
JP5490972B2 (ja) * 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
JP2004538287A (ja) * 2001-07-25 2004-12-24 プロテイン デザイン ラブス インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
US8257703B2 (en) 2003-07-15 2012-09-04 Chugai Seiyaku Kabushiki Kaisha Anti-ganglioside antibodies and compositions
JP4762717B2 (ja) * 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
JPWO2005035574A1 (ja) * 2003-10-09 2008-02-14 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
JPWO2005035573A1 (ja) * 2003-10-09 2008-01-17 中外製薬株式会社 タンパク質溶液の安定化方法
US8920797B2 (en) 2003-10-09 2014-12-30 Chugai Seiyaku Kabushiki Kaisha Highly concentrated stabilized IgM solution
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
JP2010522208A (ja) * 2007-03-22 2010-07-01 イムクローン・リミテッド・ライアビリティ・カンパニー 安定な抗体処方物
JP2008303176A (ja) * 2007-06-07 2008-12-18 Kobayashi Pharmaceut Co Ltd タンパク質含有組成物
JP2012158615A (ja) * 2012-05-28 2012-08-23 Kobayashi Pharmaceutical Co Ltd 還元糖によるタンパク質変性を抑制する方法

Also Published As

Publication number Publication date
DK0841067T3 (da) 2002-07-15
AU1337592A (en) 1992-10-06
WO1992015331A1 (en) 1992-09-17
EP0841067B1 (en) 2002-05-22
FI924982A7 (fi) 1992-11-04
DK0531539T3 (da) 1998-10-12
AU645187B2 (en) 1994-01-06
EP0841067A1 (en) 1998-05-13
FI924982A0 (fi) 1992-11-04
NO924279L (no) 1992-11-06
EP0531539A4 (OSRAM) 1995-04-05
FI924982L (fi) 1992-11-04
DE69225757D1 (de) 1998-07-09
US5908826A (en) 1999-06-01
DE69232617T2 (de) 2002-10-31
EP0531539A1 (en) 1993-03-17
EP0531539B1 (en) 1998-06-03
CA2082169A1 (en) 1992-09-09
NO924279D0 (no) 1992-11-06
DE69225757T2 (de) 1998-12-03
DE69232617D1 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
JPH0565233A (ja) モノクローナル抗体含有凍結乾燥製剤
JP4317010B2 (ja) ＩｇＧ抗体の安定な凍結乾燥医薬製剤
AU772940B2 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
KR100501263B1 (ko) 정맥 주사용 면역글로불린의 제조 방법 및 그 외의 면역글로불린 제품
JP4948407B2 (ja) 安定化処方
EP0597101B1 (en) STABILIZED HUMAN MONOCLONAL CLN-IgG ANTIBODY PREPARATION
US4849508A (en) Pasteurization of immunoglobulin solutions
JP4890537B2 (ja) 安定化抗ｂ型肝炎ウイルス（ｈｂｖ）抗体製剤
JP5638628B2 (ja) 持続型エリスロポエチン結合体の液剤
JPH0278635A (ja) ＩｇＭを含有する静脈内投与のポリクローナル免疫グロブリン調製物の調製方法
US6165467A (en) Stabilized human monoclonal antibody preparation
JPH03204822A (ja) 非変性静脈内投与可能なＩｇＭ―及び／又は／ＩｇＡ―含有免疫グロブリン製剤及びその製造方法
EP0118462A1 (en) STABILIZED CONCENTRATE OF GAMMA GLOBULINE.
JPH04346934A (ja) γ−グロブリンの液状製剤
Gayathri et al. Using Freeze-Drying to Stabilize
US20240417445A1 (en) Method for producing a lyophilized composition comprising polyclonal igm and composition obtained
WO2025173024A1 (en) Purification process and formulation of recombinant anti rhd monoclonal antibodies
JP2023501155A (ja) クリザンリズマブ含有抗体製剤
HK40011725A (en) Anti-rsv monoclonal antibody formulation
HK40010132B (zh) 重组单克隆抗TNF α 抗体的水性药用组合物
BRPI9715268B1 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção